Oliver Sartor

44.6k total citations · 13 hit papers
664 papers, 22.8k citations indexed

About

Oliver Sartor is a scholar working on Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging and Oncology. According to data from OpenAlex, Oliver Sartor has authored 664 papers receiving a total of 22.8k indexed citations (citations by other indexed papers that have themselves been cited), including 526 papers in Pulmonary and Respiratory Medicine, 275 papers in Radiology, Nuclear Medicine and Imaging and 226 papers in Oncology. Recurrent topics in Oliver Sartor's work include Prostate Cancer Treatment and Research (506 papers), Radiopharmaceutical Chemistry and Applications (258 papers) and Prostate Cancer Diagnosis and Treatment (131 papers). Oliver Sartor is often cited by papers focused on Prostate Cancer Treatment and Research (506 papers), Radiopharmaceutical Chemistry and Applications (258 papers) and Prostate Cancer Diagnosis and Treatment (131 papers). Oliver Sartor collaborates with scholars based in United States, United Kingdom and Canada. Oliver Sartor's co-authors include Johann S. de Bono, Stéphane Oudard, Liji Shen, Karim Fizazi, Mustafa Özgüroğlu, Steinbjørn Hansen, I. Bodrogi, Ivo Kocák, Gwénaëlle Gravis and Mary J. MacKenzie and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

Oliver Sartor

636 papers receiving 22.3k citations

Hit Papers

Prednisone plus cabazitaxel or mitoxantrone for metastati... 2009 2026 2014 2020 2010 2021 2020 2020 2009 500 1000 1.5k 2.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
    2010 2.4k citations Johann S. de Bono, Stéphane Oudard et al. profile →
  2. Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
    2021 1.5k citations Oliver Sartor, Johann S. de Bono et al. profile →
  3. Olaparib for Metastatic Castration-Resistant Prostate Cancer
    2020 1.4k citations Johann S. de Bono, Karim Fizazi et al. profile →
  4. Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer
    2020 474 citations Karim Fizazi, Fred Saad et al. profile →
  5. Prostate Specific Antigen Best Practice Statement: 2009 Update
    2009 390 citations Oliver Sartor, Janet L. Stanford et al. profile →
  6. Metastatic Prostate Cancer
    2018 361 citations Oliver Sartor, Johann S. de Bono profile →
  7. Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial
    2014 290 citations Oliver Sartor, John Logue et al. profile →
  8. Adjuvant and Salvage Radiotherapy After Prostatectomy: AUA/ASTRO Guideline
    2013 289 citations Oliver Sartor et al. profile →
  9. Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer
    2017 251 citations Wanling Xie, Meredith M. Regan et al. Journal of Clinical Oncology profile →
  10. Prevalence of Germline Variants in Prostate Cancer and Implications for Current Genetic Testing Guidelines
    2019 240 citations Elisa M. Ledet, Oliver Sartor et al. profile →
  11. Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial
    2023 132 citations Fred Saad, Oliver Sartor et al. profile →
  12. Phase 1/2 study of ARV-110, an androgen receptor (AR) PROTAC degrader, in metastatic castration-resistant prostate cancer (mCRPC).
    2022 125 citations Oliver Sartor, Arash Rezazadeh Kalebasty et al. Journal of Clinical Oncology profile →
  13. Theranostics and artificial intelligence: new frontiers in personalized medicine
    2024 52 citations Gokce Belge Bilgin, Brian J. Burkett et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Oliver Sartor United States 71 15.4k 8.0k 6.2k 5.1k 4.5k 664 22.8k
Mario A. Eisenberger United States 74 21.3k 1.4× 8.5k 1.1× 6.1k 1.0× 5.1k 1.0× 6.4k 1.4× 380 27.2k
Tomasz M. Beer United States 59 10.8k 0.7× 6.1k 0.8× 3.6k 0.6× 4.3k 0.8× 4.3k 0.9× 406 18.0k
Neal D. Shore United States 59 17.0k 1.1× 9.5k 1.2× 5.6k 0.9× 4.9k 0.9× 4.8k 1.1× 768 25.3k
Michael A. Carducci United States 84 17.4k 1.1× 11.4k 1.4× 4.9k 0.8× 10.8k 2.1× 6.8k 1.5× 591 32.3k
Celestia S. Higano United States 68 16.6k 1.1× 10.3k 1.3× 4.8k 0.8× 7.0k 1.4× 5.8k 1.3× 386 27.1k
Christopher J. Logothetis United States 75 9.6k 0.6× 7.9k 1.0× 2.9k 0.5× 6.9k 1.3× 3.7k 0.8× 458 20.8k
George Wilding United States 72 12.1k 0.8× 6.8k 0.9× 1.9k 0.3× 9.9k 1.9× 5.3k 1.2× 308 22.3k
Fred Saad Canada 83 23.9k 1.6× 15.4k 1.9× 8.7k 1.4× 7.6k 1.5× 6.9k 1.5× 1.2k 36.7k
Ronald de Wit Netherlands 67 13.4k 0.9× 10.2k 1.3× 4.1k 0.7× 4.5k 0.9× 4.5k 1.0× 373 26.4k
Cora N. Sternberg United States 76 21.0k 1.4× 12.1k 1.5× 5.0k 0.8× 7.6k 1.5× 6.6k 1.5× 583 34.5k

Countries citing papers authored by Oliver Sartor

Since Specialization
Citations

This map shows the geographic impact of Oliver Sartor's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Oliver Sartor with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Oliver Sartor more than expected).

Fields of papers citing papers by Oliver Sartor

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Oliver Sartor. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Oliver Sartor. The network helps show where Oliver Sartor may publish in the future.

Co-authorship network of co-authors of Oliver Sartor

This figure shows the co-authorship network connecting the top 25 collaborators of Oliver Sartor. A scholar is included among the top collaborators of Oliver Sartor based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Oliver Sartor. Oliver Sartor is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Bilgin, Gokce Belge, Brian J. Burkett, Cem Bilgin, et al.. (2024). Neurologic Symptoms After177Lu-Prostate-Specific-Membrane Antigen-617 Therapy: A Single-Center Experience. Journal of Nuclear Medicine. 65(9). 1402–1408.
3.
Calais, Jérémie, Michael J. Morris, A. Tuba Kendi, et al.. (2024). Best Patient Care Practices for Administering PSMA-Targeted Radiopharmaceutical Therapy. Journal of Nuclear Medicine. 65(11). 1666–1671. 5 indexed citations
4.
5.
Calais, Jérémie, Vishnu Murthy, Andrew F. Voter, et al.. (2024). Efficacy and toxicity of [177Lu]Lu-PSMA-617 for metastatic castration-resistant prostate cancer in a real-world setting: Results from the U.S. Expanded Access Program and comparisons with phase 3 VISION data.. Journal of Clinical Oncology. 42(16_suppl). e17061–e17061. 1 indexed citations
6.
Jang, Albert, A. Tuba Kendi, Geoffrey B. Johnson, Þorvarður R. Hálfdánarson, & Oliver Sartor. (2023). Targeted Alpha-Particle Therapy: A Review of Current Trials. International Journal of Molecular Sciences. 24(14). 11626–11626. 55 indexed citations
7.
Pomykala, Kelsey L., Boris Hadaschik, Oliver Sartor, et al.. (2023). Next generation radiotheranostics promoting precision medicine. Annals of Oncology. 34(6). 507–519. 42 indexed citations
8.
Chen, Wenzhou, Audrey Dang, Brian Lewis, et al.. (2022). Embracing the Practical Aspects of Theranostics With Prostate-Specific Membrane Antigen–Targeted Lutetium-177. Practical Radiation Oncology. 12(4). 300–304. 3 indexed citations
9.
Zhang, Wensheng, Yan Dong, Oliver Sartor, & Kun Zhang. (2021). Comprehensive Analysis of Multiple Cohort Datasets Deciphers the Utility of Germline Single-Nucleotide Polymorphisms in Prostate Cancer Diagnosis. Cancer Prevention Research. 14(7). 741–752. 2 indexed citations
10.
Marshall, Catherine H., Wei Fu, Hao Wang, et al.. (2021). Randomized Phase II Trial of Sipuleucel-T with or without Radium-223 in Men with Bone-metastatic Castration-resistant Prostate Cancer. Clinical Cancer Research. 27(6). 1623–1630. 39 indexed citations
11.
Delanoy, Nicolas, Debbie Robbrecht, Mario A. Eisenberger, et al.. (2021). Pain Progression at Initiation of Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Post Hoc Analysis of the PROSELICA Study. Cancers. 13(6). 1284–1284. 5 indexed citations
12.
Chau, Cindy H., et al.. (2020). PARP Inhibitors and Prostate Cancer: To Infinity and BeyondBRCA. The Oncologist. 26(1). e115–e129. 71 indexed citations
13.
Qu, Fangfang, Wanling Xie, Mari Nakabayashi, et al.. (2016). Association of AR-V7 and Prostate-Specific Antigen RNA Levels in Blood with Efficacy of Abiraterone Acetate and Enzalutamide Treatment in Men with Prostate Cancer. Clinical Cancer Research. 23(3). 726–734. 73 indexed citations
14.
Yang, Zhan, Guanyi Zhang, Xiaojie Wang, et al.. (2016). Interplay between Cytoplasmic and Nuclear Androgen Receptor Splice Variants Mediates Castration Resistance. Molecular Cancer Research. 15(1). 59–68. 55 indexed citations
15.
Sartor, Oliver, et al.. (2015). Neoadjuvant Tyrosine Kinase Downstaging of T2 Renal Cell Carcinoma in Solitary Kidney Before Robotic Partial Nephrectomy. Journal of Endourology Case Reports. 1(1). 47–49. 1 indexed citations
16.
Zhang, Qiuyang, Sen Liu, Dongxia Ge, et al.. (2012). Interleukin-17 Promotes Formation and Growth of Prostate Adenocarcinoma in Mouse Models. Cancer Research. 72(10). 2589–2599. 85 indexed citations
17.
Koochekpour, Shahriar, Sunipa Majumdar, Gissou Azabdaftari, et al.. (2012). Serum Glutamate Levels Correlate with Gleason Score and Glutamate Blockade Decreases Proliferation, Migration, and Invasion and Induces Apoptosis in Prostate Cancer Cells. Clinical Cancer Research. 18(21). 5888–5901. 115 indexed citations
18.
Li, Jing, Bo Cao, Xichun Liu, et al.. (2011). Berberine Suppresses Androgen Receptor Signaling in Prostate Cancer. Molecular Cancer Therapeutics. 10(8). 1346–1356. 81 indexed citations
19.
Penney, Kathryn L., Claudia A. Salinas, Mark M. Pomerantz, et al.. (2009). Evaluation of 8q24 and 17q Risk Loci and Prostate Cancer Mortality. Clinical Cancer Research. 15(9). 3223–3230. 42 indexed citations
20.
Ross, Robert W., William Oh, Wanling Xie, et al.. (2008). Inherited Variation in the Androgen Pathway Is Associated With the Efficacy of Androgen-Deprivation Therapy in Men With Prostate Cancer. Journal of Clinical Oncology. 26(6). 842–847. 90 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mario A. Eisenberger Breakdown of academic impact, for papers by Tomasz M. Beer Breakdown of academic impact, for papers by Neal D. Shore Breakdown of academic impact, for papers by Michael A. Carducci Breakdown of academic impact, for papers by Celestia S. Higano Breakdown of academic impact, for papers by Christopher J. Logothetis Breakdown of academic impact, for papers by George Wilding Breakdown of academic impact, for papers by Fred Saad Breakdown of academic impact, for papers by Ronald de Wit Breakdown of academic impact, for papers by Cora N. Sternberg
Rankless by CCL
2026